N1-(2-(1H-Indol-3-yl)ethyl)-n4-(pyridin-4-yl)benzene-1,4-diamine
| Title | Journal |
|---|---|
| Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. | Cell death & disease 20170601 |
| Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma. | Oncogene 20160714 |
| JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. | Oncotarget 20151110 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20110714 |
| Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. | British journal of haematology 20100501 |
| Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. | Leukemia research 20100201 |
| JNJ-26481585, a novel 'second-generation' oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091115 |
| Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. | Cancer research 20090701 |
| Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. | Anti-cancer drugs 20090601 |